RUBICON · NSE
Rubicon Research Limited
₹1,751.1
-1.53% (-₹27.2)
Prev. close
₹1,778.3
Volume
4,70,413
Delivery %
60.8%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Rubicon Research Limited
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant. Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies. The company was incorporated in 1999 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Parag Suganchand Sancheti
Headquarters
Mumbai
Employees
1,290
Website
rubicon.co.inExchange
View on NSE ↗Key stats
Market cap
₹28,909.28 Cr
P/E ratio (TTM)
100.5
Dividend yield
0.08%
EPS (TTM)
₹17.43
Beta (1Y · daily vs NIFTY 50)
0.33
Shares float
5.53 Cr
EPS · quarter ended Jun 2026
₹5.08
Financial Performance
01 · Financials
FY26 growth needs FY25 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY25 | FY26 |
|---|---|---|
| ₹1,267.10 Cr | ₹1,753.96 Cr | |
| EBITDA | ₹265.79 Cr | ₹407.96 Cr |
| — | ₹246.74 Cr | |
| Diluted EPS | — | ₹15.31 |
Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, Net income, Pretax income, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY25 | FY26 |
|---|---|---|
| ₹1,451.43 Cr | ₹2,326.71 Cr | |
| ₹417.61 Cr | ₹311.01 Cr | |
| Stockholders' equity | ₹540.98 Cr | ₹1,288.82 Cr |
Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY25 | FY26 |
|---|---|---|
| — | ₹205.05 Cr | |
| Investing cash flow | — | ₹-409.72 Cr |
| — | ₹283.07 Cr | |
| Capital expenditure | — | ₹-229.17 Cr |
| End cash position | — | ₹185.65 Cr |
Operating cash flow, Depreciation & amortization, Investing cash flow, Financing cash flow, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Oct 25–Dec 25(2Q) | Mar 26 | Jun 26 |
|---|---|---|---|
| Promoter | 59.99% | 59.86% | 59.76% |
| Public | 40.01% | 40.14% | 40.24% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Rubicon Research Limited | ₹29,358.33 Cr | ₹1,751.1 | 101.7 | 22.78 | 19.1% | 0.24 | +36.6% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
13 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Rubicon Research Ltd Dividend History, Yield & Record Date
Rubicon Research Ltd declared a final dividend of ₹1.50 per share on May 29, 2026. The record date for this dividend is August 7, 2026. The company typically pays one dividend annually and has a low dividend yield of 0.08%.
Rubicon Research - Multibagger Stocks: 14 microcaps surged up to 355% in just 6 months
The Economic Times · 9 days ago